News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
399,790 Results
Type
Article (34658)
Company Profile (71)
Press Release (365051)
Multimedia
Podcasts (94)
Webinars (9)
Section
Business (103016)
Career Advice (2578)
Deals (18649)
Drug Delivery (109)
Drug Development (50581)
Employer Resources (155)
FDA (9668)
Job Trends (9678)
News (185545)
Policy (19654)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2122)
Accelerated approval (23)
Adcomms (25)
Allergies (101)
Alliances (25784)
ALS (122)
Alzheimer's disease (1182)
Antibody-drug conjugate (ADC) (226)
Approvals (9817)
Artificial intelligence (336)
Autoimmune disease (100)
Automation (19)
Bankruptcy (135)
Best Places to Work (7866)
BIOSECURE Act (10)
Biosimilars (125)
Biotechnology (46)
Bladder cancer (103)
Brain cancer (45)
Breast cancer (447)
Cancer (3257)
Cardiovascular disease (305)
Career advice (2190)
Career pathing (37)
CAR-T (202)
CDC (43)
Celiac Disease (1)
Cell therapy (497)
Cervical cancer (24)
Clinical research (43163)
Collaboration (973)
Company closure (3)
Compensation (718)
Complete response letters (43)
COVID-19 (2184)
CRISPR (69)
C-suite (378)
Cystic fibrosis (97)
Data (4324)
Decentralized trials (1)
Denatured (10)
Depression (104)
Diabetes (368)
Diagnostics (3966)
Digital health (30)
Diversity (5)
Diversity, equity & inclusion (40)
Drug discovery (155)
Drug pricing (162)
Drug shortages (25)
Duchenne muscular dystrophy (161)
Earnings (50843)
Editorial (59)
Employer branding (18)
Employer resources (138)
Events (61987)
Executive appointments (425)
FDA (11646)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (12)
Funding (810)
Gene editing (149)
Generative AI (31)
Gene therapy (479)
GLP-1 (738)
Government (3582)
Grass and pollen (3)
Guidances (258)
Healthcare (12260)
HIV (46)
Huntington's disease (32)
IgA nephropathy (59)
Immunology and inflammation (178)
Immuno-oncology (39)
Indications (65)
Infectious disease (2374)
Inflammatory bowel disease (119)
Inflation Reduction Act (12)
Influenza (77)
Intellectual property (120)
Interviews (466)
IPO (9360)
IRA (45)
Job creations (2088)
Job search strategy (1782)
JPM (56)
Kidney cancer (13)
Labor market (65)
Layoffs (426)
Leadership (38)
Legal (4269)
Liver cancer (56)
Longevity (13)
Lung cancer (461)
Lymphoma (291)
Machine learning (26)
Management (54)
Manufacturing (502)
MASH (129)
Medical device (7837)
Medtech (7874)
Mergers & acquisitions (9938)
Metabolic disorders (965)
Multiple sclerosis (116)
NASH (21)
Neurodegenerative disease (211)
Neuropsychiatric disorders (70)
Neuroscience (2025)
Neurotech (1)
NextGen: Class of 2026 (4336)
Non-profit (3374)
Now hiring (24)
Obesity (461)
Opinion (285)
Ovarian cancer (126)
Pain (118)
Pancreatic cancer (165)
Parkinson's disease (194)
Partnered (24)
Patents (235)
Patient recruitment (279)
Peanut (42)
People (22870)
Pharmaceutical (23)
Pharmacy benefit managers (18)
Phase 1 (12375)
Phase 2 (18747)
Phase 3 (15948)
Pipeline (3355)
Policy (230)
Postmarket research (1696)
Preclinical (5159)
Press Release (34)
Prostate cancer (149)
Psychedelics (36)
Radiopharmaceuticals (147)
Rare diseases (629)
Real estate (3205)
Recruiting (68)
Regulatory (14792)
Reports (28)
Research institute (1788)
Resumes & cover letters (431)
Rett syndrome (27)
RNA editing (16)
RSV (61)
Schizophrenia (107)
Series A (127)
Series B (96)
Service/supplier (4)
Sickle cell disease (70)
Special edition (17)
Spinal muscular atrophy (135)
Sponsored (38)
Startups (1981)
State (1)
Stomach cancer (12)
Supply chain (60)
Tariffs (69)
The Weekly (82)
Vaccines (768)
Venture capital (70)
Weight loss (336)
Women's health (59)
Worklife (22)
Date
Last 7 days (381)
Last 30 days (1314)
Last 365 days (18985)
2026 (1726)
2025 (19202)
2024 (21126)
2023 (23711)
2022 (30573)
2021 (34411)
2020 (33020)
2019 (29321)
2018 (22554)
2017 (18892)
2016 (18895)
2015 (21432)
2014 (15556)
2013 (12830)
2012 (13513)
2011 (14252)
2010 (12202)
Location
Africa (657)
Alabama (45)
Alaska (3)
Arizona (156)
Arkansas (8)
Asia (24158)
Australia (4071)
California (6620)
Canada (2069)
China (724)
Colorado (293)
Connecticut (279)
Delaware (244)
Europe (55337)
Florida (1048)
Georgia (220)
Hawaii (1)
Idaho (36)
Illinois (555)
India (34)
Indiana (342)
Iowa (9)
Japan (281)
Kansas (87)
Kentucky (23)
Louisiana (13)
Maine (32)
Maryland (850)
Massachusetts (4651)
Michigan (162)
Minnesota (357)
Mississippi (5)
Missouri (66)
Montana (13)
Nebraska (13)
Nevada (78)
New Hampshire (49)
New Jersey (2003)
New Mexico (12)
New York (1867)
North Carolina (922)
North Dakota (3)
Northern California (3207)
Ohio (165)
Oklahoma (8)
Oregon (22)
Pennsylvania (1334)
Puerto Rico (14)
Rhode Island (30)
South America (917)
South Carolina (26)
South Dakota (1)
Southern California (2684)
Tennessee (110)
Texas (949)
United States (23754)
Utah (207)
Virginia (144)
Washington D.C. (44)
Washington State (472)
West Virginia (4)
Wisconsin (50)
399,790 Results for "one drop".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; Novartis’ CEO also downplayed the impact of Big Pharma pricing deals with the Trump administration; Regeneron continued the trend of dropping cell therapy assets;
BioSpace
takes a look at how the FDA is functioning mid-shutdown.
October 29, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
·
8 min read
Earnings
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing
The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting campaign is helping to stem the downward trend.
November 6, 2025
·
2 min read
·
Dan Samorodnitsky
Drug pricing
Senate Republicans Drop Orphan Drug Exemptions From ‘One Big Beautiful Bill’
The new version of the bill will still need to go through the entire House and Senate.
June 18, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
A mid-stage study for ABI-5366 will begin mid next year, while Assembly continues to assess the Phase II potential of ABI-1179.
December 9, 2025
·
2 min read
·
Tristan Manalac
Earnings
Merck Vaccine Sales Drop as US Declines Strike Another Pharma
While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.
October 30, 2025
·
1 min read
·
Dan Samorodnitsky
Job Trends
Hiring Outlook: Job Openings Will Likely Drop as 2025 Winds Down But Could Rise in 2026
Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, based on
BioSpace
data. However, hundreds of open roles are expected this year in Massachusetts, and a job market turnaround could start late next year.
November 20, 2025
·
4 min read
·
Angela Gabriel
Drug pricing
Novo, Lilly Shares Drop as Trump Promises $150 Ozempic
CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, or any other GLP-1 drugmaker.
October 17, 2025
·
3 min read
·
Annalee Armstrong
Autoimmune disease
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.
March 19, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
November 21, 2025
·
1 min read
1 of 39,979
Next